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Abstract
Introduction: Pregnant women require about 250 μg of iodine daily. Hypothyroid women treated with L-thyroxine do not utilise iodine, 
and metabolism of L-thyroxine tablets is an additional source of iodine for their foetuses. 
The aim of the study was to evaluate the influence of iodine supplementation in hypothyroid pregnant women treated with L-thyroxine 
on neonate TSH concentration and maternal thyroid parameters.
Material and methods: Ninety-two pregnant women with primary hypothyroidism on adequate thyroid hormone replacement were 
voluntarily divided into two groups: “thyroxine” (n = 38) treated with L-thyroxine only, and “thyroxine + iodine” (n = 54) treated ad-
ditionally with 150 μg/day of iodine since 10th gestational week.
Primary outcomes were the maternal thyroid function tests (TSH, fT4, fT3) and neonatal TSH concentrations at the 3–4th day of life. Urinary 
iodine concentration was measured at first and third trimester to compare iodine status in both groups.
Results: Iodine supplementation significantly increased median urinary ioduria in the third trimester (from 95.15 μg/L to 151.50 μg/L), but 
did not prevent the decrease of maternal fT4 and fT3 concentrations in the second and third trimester. Median neonate TSH concentration 
in both groups was within normal range, but was 33% higher in the “thyroxine + iodine” than in the “thyroxine” group (1.91 mU/L vs. 
1.34 mU/L). Moreover, 8.77% of newborns in the “thyroxine + iodine” group had TSH > 5 mIU/L. 
Conclusions: We did not find evidence for a positive influence of iodine supplementation on thyroid function of either hypothyroid 
pregnant women sufficiently treated with L-thyroxine or their neonates. (Endokrynol Pol 2016; 67 (4): 367–374)
Key words: pregnancy; hypothyroidism; iodine supplementation; neonatal TSH; ioduria
Streszczenie
Wstęp: U ciężarnych rekomendowana jest zwiększona podaż jodu pokrywająca zapotrzebowanie kobiety i dziecka. Tarczyca ciężarnej 
z niedoczynnością nie zużywa jodu. Jod dostarczony w diecie, suplementach oraz pochodzący z metabolizmu tyroksyny stanowi źródło 
wyłącznie dla płodu. 
Celem pracy była ocena wpływu suplementacji jodowej u ciężarnych z niedoczynnością tarczycy na stężenia TSH noworodków i para-
metry tarczycowe matek.
Materiał i metody: Badanie przeprowadzono w grupie 92 ciężarnych z pierwotną niedoczynnością tarczycy wyrównaną w trakcie le-
czenia L-tyroksyną podzielono na dwie grupy: „tyroksyna” (n = 38) leczone jedynie tyroksyną i “tyroksyna + jod” (n = 54) otrzymujące 
tyroksynę i od 10. tygodnia ciąży jod 150 μg/dobę.
U matek oznaczano TSH, fT4, fT3 w każdym trymestrze a u noworodków TSH w 3–4 dobie życia. Zaopatrzenie w jod oceniano na pod-
stawie jodurii badanej w 1. i 3. trymestrze.
Wyniki: Suplementacja jodowa spowodowała istotne zwiększenie mediany jodurii z 95,15 μg/l do 151,50 μg/l, jednak nie zapobiegła 
obniżeniu stężeń fT4 i fT3 w 2. i 3. trymestrze. W obu grupach mediana stężeń TSH noworodków utrzymywała się w granicach normy, 
ale była o 33% wyższa w grupie „tyroksyna + jod” niż w grupie „tyroksyna”(1,91 mU/l vs. 1,34 mU/l). Tylko w grupie „tyroksyna + jod” 
stwierdzono u noworodków stężenie TSH > 5 mIU/l co dotyczyło 8,77% badanych.
Wnioski: Nie uzyskano dowodów na pozytywny wpływ suplementacji jodowej u ciężarnych z niedoczynnością tarczycy właściwie 
wyrównanych L-tyroksyną na TSH noworodków. Nie zaznaczył się także wpływ na parametry tarczycowe u kobiety ciężarnej. 
(Endokrynol Pol 2016; 67 (4): 367–374)
Słowa kluczowe: ciąża; niedoczynność tarczycy; suplementacja jodowa; TSH noworodków; joduria
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Introduction
Iodine deficiency during pregnancy may result in insuf-
ficient maternal and foetal thyroid hormone synthesis 
and may lead to impaired brain development of the 
child [1]. On the other hand, iodine excess may inhibit 
foetal thyroid, which begins to synthesise thyroid hor-
mones at about the 10th week of pregnancy [2], causing 
hypothyroidism and goitre [3].
The assessment of iodine intake in the population 
can be made using urinary iodine concentration and 
indirectly by measurement of TSH concentration in 
neonates [4]. According to WHO experts, the median 
urinary iodine concentration in pregnant women is 
between 150 and 249 μg/L, and a percentage of neonates 
in their 3rd–4th day of life with TSH level higher than 
5 mU/L below 3% indicates adequate iodine intake [5]. 
With reference to increased dietary iodine require-
ments during pregnancy, WHO/UNICEF/ICCIDD rec-
ommend a daily iodine intake during pregnancy of 200 
to 300 μg, mean 250 μg, maximally 500 μg [4]. Therefore, 
to ensure an adequate iodine supply for the mother 
and her child in many European countries pregnant 
and breastfeeding women are advised to receive an 
additional daily oral dose of 100–200 μg of potassium 
iodide. There is no separate recommendation for hy-
pothyroid women in whom the thyroid gland is not 
able to synthesise hormones and who are treated with 
L-thyroxine. In these cases, not only iodine provided 
with food and released during metabolism of maternal 
hormones, but also iodine derived from L-thyroxine 
tablets remains at the disposal of the child’s thyroid 
[6]. Following the metabolism of 100 μg of L-thyroxine, 
about 60 μg of iodine is released, which, together with 
the dietary iodine intake pool, remains at the disposal 
of the thyroid of the child [6]. The neonate thyroid 
hormone synthesis begins at about the 10th week of 
pregnancy. To the best of our knowledge, there are no 
data available regarding iodine supplementation in 
pregnant hypothyroid women treated with substitutive 
doses of L-thyroxine. Thus, we aimed to estimate the 
influence of iodine supplementation in hypothyroid 
pregnant women receiving L-thyroxine on their thyroid 
status evaluated by measurement of TSH, fT3, and fT4 
concentrations, as well as on the thyroid function of 
their newborns assessed by neonate TSH concentration. 
Material and methods
Subjects
The study population included 96 pregnant Caucasian 
women with a history of primary hypothyroidism. All 
participants were consecutively recruited from a single 
endocrinology outpatient clinic. The study lasted from 
2008 until 2013. 
Ninety-two patients completed the study because 
there were two miscarriages at the 12th week of gesta-
tion, one missed abortion at the 26th weeks of gesta-
tion, and one missed data collection due to refusal to 
continue the study.
Seventeen of the patients were treated because 
of subclinical hypothyroidism, in all cases caused by 
Hashimoto disease. All patients were physically exam-
ined and had TSH, fT3, and fT4 concentrations meas-
ured every 4–6 weeks. They were on a standard diet and 
were treated with L-thyroxine only before pregnancy 
and until the end of the 10th week of gestation. Thereaf-
ter, the studied group was divided into two subgroups: 
the “thyroxine” group, consisting of 38 subjects who 
continued with appropriate dose of L-thyroxine only; 
and the “thyroxine + iodine” group — 54 subjects who 
additionally to L-thyroxine received a standard dose of 
150 μg iodine daily as potassium iodide in a separate pill. 
Commercially available multivitamin and mineral sup-
plements were not used. The enrolment to subgroups 
was made on a voluntary basis. The basic characteristics 
of the subgroups are presented in Table I. 
During pregnancy and perinatal period the women 
were not exposed to the iodinated contrast media, 
thyroid affecting medications, iodinated antiseptics, 
or cigarette smoking.
The study protocol was reviewed and approved by 
the Ethics Committee of the Centre of Postgraduate 
Medical Education in Warsaw, Poland. Signed informed 
consent form was obtained from all patients. 
Analytical methods
Mothers’ blood TSH, free T3 (fT3), and free T4 (fT4) 
concentrations in samples collected at 8–10, 22–24, 
and 34–36 weeks of pregnancy were used for statistical 
analysis, the first and third of them corresponding to 
the urinary iodine excretion measurements. To avoid 
confounding factors, the samples were taken in the 
morning before L-thyroxine as well as iodine inges-
tion. Serum was separated by centrifugation and the 
hormone concentration was assayed immediately.
Quantitative analyses of TSH, fT3, and fT4 were per-
formed by a chemiluminescent immunoassay (EURO/
DPC, UK) using an Immulite 2000 automatic analyser. 
The manufacturer’s reference ranges for non-pregnant 
adult in these kits were as follows: TSH 0.4-4.0 mIU/L 
(sensitivity 0.004 mIU/L, intra-assay coefficient of vari-
ance — CV 3.8–12.5%), fT4 11.5–22.7 pmol/L (sensitivity 
3.2 pmol/L, intra-assay CV 3.0–7.8%), and fT3 1.8– 
–4.2 pg/mL (sensitivity 1.0 pg/mL, intra-assay CV 
4.3–9.1%), respectively.
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Urinary iodine excretion was evaluated in every 
subject in the 1st and 3rd trimester of pregnancy. Tak-
ing into account the high diurnal and day-to-day vari-
ability of urinary iodine excretion, we assessed urinary 
iodine concentration for every pregnant subject four 
times: twice at the 10th week of gestation and twice 
at the 34th-36th week of gestation. It was measured in 
a spot of morning urine sample by the catalytic cerium/ 
/arsenic method based on the Sandell-Kolthoff reaction, 
which was preceded by alkaline ashing [7]. TSH con-
centration in neonates was evaluated as a part of the 
neonatal screening protocol. The procedure is based on 
determination of TSH by a two-site IRMA method in 
dried blood spots obtained by the heel puncture at the 
3rd–4th day of life. In Poland, values ≥ 15 mIU/L in whole 
blood are considered abnormal and require further as-
sessment for congenital hypothyroidism.
Statistical analyses
Statistical analyses were performed using STATISTICA 
9.0 PL.
The Kolmogorov-Smirnov test was used to estimate 
the normal distribution of evaluated parameters. The 
Student t test was used for normally distributed data, 
while Wilcoxon-matched-paired test and the Bonferoni-
Holm adjustment were used for data not normally 
distributed. The Spearman test was performed to cal-
culate the correlations between groups. The values 
were reported as median, minimum, and maximum. 
Statistical significance was accepted at P < 0.05.
Results
All women remained euthyroid throughout pregnancy, 
and that fact was confirmed by serum TSH level, 
adopted as a concentration above 0.4 mIU/L and below 
2.5 mIU/L. Their serum fT4 and fT3 concentrations re-
mained within normal range for the general population.
Median urinary iodine concentration at the 10th 
week of pregnancy was below the optimal range for 
pregnant women both in the “thyroxine” and “thyrox-
ine + iodine” groups (median ± IQR: 83.15 ± 41.03 μg/L 
and 95.15 ± 69.45 μg/L, respectively), which indicated 
mild iodine deficiency according to the WHO criteria 
(Fig. 1). In the first trimester, only 5 of 38 women of 
the “thyroxine” group and 11 of 54 patients of the 
Table I. Basic characteristics of the studied groups
Tabela I. Podstawowa charakterystyka badanych grup
Parameters “Thyroxine” group “Thyroxine + iodine” group 
Number of patients 38 54
Aetiology of hypothyroidism:
Hashimoto’s thyroiditis 31 46
Thyroidectomy propter nodular thyroid disease 2 2
Thyroidectomy propter Graves’ disease 1 1
Thyroidectomy and radioiodine therapy propter thyroid cancer 0 1
Thyroidectomy, radioiodine and external radiotherapy propter thyroid cancer 1 0
Radioiodine therapy propter Graves’ disease 2 4
Thyroidectomy and radioiodine therapy propter Graves’ disease and thyroid cancer 1 0
Severity of hypothyroidism
overt 27 46
subclinical 9 8
Coexisting disorders:
Celiac disease 1 0
Pernicious anaemia 1 0
Hypoparathyroidism 1 0
Diabetes type 1 0 1
Conception:
Natural 38 47
In vitro fertilisation 0 6
Insemination 0 1
Age (years) mean ± SD 30.16 ± 3.5 30.10 ± 3.53
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“thyroxine and iodine” group had adequate urinary 
iodine excretion (Fig. 2). Introduction of iodine supple-
mentation in the “thyroxine + iodine” group resulted 
in a significant increase of median urinary iodine con-
centration at the 3rd trimester up to 151.50 ± 80.77 μg/L 
(p < 0.001), while in the “thyroxine” group the median 
urinary iodine excretion did not change and remained 
low (101.09 ± 81.66 μg/L). The percentage of individuals 
with urinary iodine concentration over 150 μg/L in the 
“thyroxine + iodine” group increased significantly but 
remained steady in the group treated with thyroxine 
alone (Fig. 2).
In both groups, serum fT4 concentrations signifi-
cantly decreased in the second and third trimester when 
compared with the first. In the “thyroxine + iodine” 
group, TSH and fT3 levels were also significantly lower in 
the third trimester when compared with the first (Fig. 1). 
TSH and fT3 concentrations did not differ between 
the “thyroxine” and “thyroxine + iodine” groups in 
any trimester, while fT4 level was lower in the third 
trimester in the “thyroxine + iodine” group. 
Table II. Selected parameters in pregnant hypothyroid women and their offspring
Tabela II. Wybrane parametry u kobiet ciężarnych z niedoczynnością tarczycy i ich dzieci
Patient
Time of examination
Parameter “Thyroxine” group “Thyroxine + iodine” group p
Mother 
First trimester
Thyroxine dose [µg/d]
mean ± SD 86.40 ± 44.60 83.142 ± 38.32 ns
range 50–200 50–175
Thyroxine dose [µg/kg/d]
mean ± SD 1.38 ± 0.46 1.40 ± 0.69 ns
range 0.51–2.21 0.62–3.12
Urinary iodine excretion [µg/L]
Median ± IQR 83.15 ± 41.03 95.15 ± 69.45 ns
Mother 
Third trimester
Thyroxine dose [µg/d]
mean ± SD 119.0 ± 51.59 100.0 ± 41.62 ns
range 75–200 100–200
Thyroxine dose [µg/kg/d]
mean ± SD 1.57 ± 0.48 1.50 ± 0.58 ns
range 0.89–2.564 0.89–2.86
Urinary iodine excretion [µg/L]
Median ± IQR 101.09 ± 81.66 151.50 ± 80.77 < 0.01
Neonate
3–4 days after birth
TSH [mU/L]
Median ± IQR 1,34 ± 2.21 1.91 ± 2.41 ns
range 0.01–3.86 0.01–9.48
Number (percentage) of newborns  
with TSH > 5mU/L
0 5/57 (8.77%)
ns — non-significant
TSH concentrations were analysed in 39 neonates 
in the “thyroxine” group and 57 in the “thyroxine 
+ iodine” group (as one of the triplets died in the first 
day of life) (Table III). The neonate TSH concentrations 
both in the “thyroxine” and the “thyroxine + iodine” 
groups were within the normal range with median TSH 
level of 1.34 mIU/L and 1.91 mIU/L, respectively, and 
did not differ between the groups. The newborn TSH 
concentration above 5 mIU/L was found in five neo-
nates (5.11, 5.33, 5.66, 7.38, and 9.26 mU/L, respectively). 
Interestingly, all of those children were from mothers 
of the “thyroxine + iodine” group (5/57 = 8.77%), 
who were treated because of overt hypothyroidism 
(four of them due to Hashimoto’s thyroiditis and one 
— after strumectomy propter nodular goitre) (Table II). 
One child with TSH concentration of 5.66 mIU/L had 
a twin brother in whom the TSH level was found to 
be 0.5 mIU/L. Duration of pregnancy did not differ 
in both groups and was 37.68 weeks and 39.0 weeks, 
respectively. The prevalence of gestational diabetes was 
similar in both groups and remained within the aver-
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age range (below 10%) for pregnant women (Table III). 
Perinatal complications occurred in two cases from 
the “thyroxine” group. One patient developed sclero-
sis multiplex and another one suffered an ischaemic 
stroke with left-sided hemiplegia. In this particular case 
previously undiagnosed foramen in atrial septum was 
found thereafter.
Discussion
There are four parameters recommended for the 
assessment of iodine status in human populations: 
urinary iodine concentration, goitre rate in school-age 
children, thyroglobulin concentration, and neonatal 
TSH concentration [2]. Urinary iodine concentration 
is a sensitive indicator of a recent, daily iodine intake. 
Thyroglobulin concentration indicates iodine supply 
during the preceding weeks to months, whereas thy-
roid volume corresponds to long-term iodine nutrition 
lasting months to years [2]. Neonatal TSH is a marker 
of iodine supply during late foetal life. 
We found it reasonable to question whether stand-
ard iodine supplementation in hypothyroid pregnant 
women on adequate thyroid hormone replacement 
influence thyroid function of their neonates. In Po-
land an iodine prophylaxis program has been imple-
mented since 1997, with modification in 2010, which 
includes mandatory iodisation of household salt with 
Figure 1. Evolution of urinary iodine, TSH, fT4, and fT3 concentrations in hypothyroid women treated with thyroxine alone or with 
thyroxine and iodine at each trimester of pregnancy. Data are presented as median ± IQR. Significant differences in urinary iodine 
excretion as well as TSH, fT4, and fT3 concentrations between the trimesters in each of the two groups are shown in the diagrams
Rycina 1. Zmiany stężeń jodu w moczu porannym oraz TSH, fT4 i fT3 w poszczególnych trymestrach ciąży u ciężarnych z niedoczynnością 
tarczycy leczonych samą L-tyroksyną lub L-tyroksyną i preparatem jodu. Dane przedstawione jako mediana ± IQR. Na wykresach 
zaznaczono istotne różnice w jodurii oraz stężeniach TSH, fT4 i fT3 pomiędzy poszczególnymi trymestrami w obu badanych grupach
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30 ± 10 mg KI/kg salt or 39 ± 13 mg KIO3/kg salt and 
supplementation of pregnant and breastfeeding women 
with an additional 150 μg of iodine daily [8]. Despite the 
fact that Poland in 2003 was considered by the WHO, 
UNICEF, and ICCIDD to be a country with sufficient 
iodine supply [9], we did not find satisfactory urinary 
iodine concentrations in the group under study. Median 
ioduria at the first trimester of gestation in hypothyroid 
women being efficiently treated with L-thyroxine was 
85.28 μg/L, which corresponds to the epidemiological 
criteria of insufficient iodine supply [10]. Before in-
troducing iodine supplementation only17.4% of our 
population of 94 subjects had urinary iodine concentra-
tion above 150 μg/L. Iodine supplementation resulted 
in an expected increase in median morning ioduria, as 
well as an increase in the percentage of patients with 
desirable urinary iodine concentration above 150 μg/L 
to 61.1%. We realise that the number of participants in 
our study is not adequate to assess iodine sufficiency 
in the population [11]; however, the increase in iodine 
urinary excretion confirms additional iodine intake in 
the “thyroxine + iodine” group.
In healthy pregnant women fT4 concentrations 
decrease at the second and third trimester [12]. This 
phenomenon was considered to be a result of changes 
in thyroxine-binding globulin and albumin concen-
trations [13, 14] or of a true hypothyroxinaemia, 
possibly reflecting iodine deficiency [15]. Brucker et 
al. reported in women with normal thyroid function 
a drop of both fT4 and fT3 levels after the first trimester 
of pregnancy, with no influence of iodine supple-
mentation [16]. Similarly, in our material of hypothy-
roid women treated with L-thyroxine, we observed 
a significant decrease of fT4 levels during pregnancy 
irrespectively of iodine supplementation, which was 
not accompanied by an increase in TSH concentra-
tion. Moreover, fT4 was significantly lower in the 
“thyroxine + iodine” than in the “thyroxine” group. 
The concentration of fT3 decreased significantly 
in the “thyroxine + iodine” group only; however, 
a similar tendency was seen in the “thyroxine” group 
(Fig. 1). Our results seem to confirm that a drop in 
fT4 and fT3 levels at second and third trimester is 
a physiological phenomenon in pregnancy and not 
a consequence of iodine deficiency. 
Proper iodine supply ensures normal thyroid func-
tion of the child, which is essential for its somatic and 
neurological development [1, 17]. Neonatal TSH is an 
important marker of iodine supply during later gesta-
tion, as its concentration correlates with the thyroid hor-
mone level of the foetus [1]. Insufficient supply of iodine 
leads to depletion of thyroid hormone production and 
consequently to overstimulation of the thyroid gland by 
TSH [18]. However, whether newborn TSH measured 
in 3–4 days after birth is a sensitive indicator of mild 
iodine deficiency during pregnancy is currently being 
discussed [19, 20]. According to the WHO criteria, in 
Table III. The course and outcome of pregnancy
Tabela III. Przebieg ciąży i porodu
“Thyroxine”  
group
“Thyroxine +  
+ iodine”  
group
Number of women 38 54
Gestational diabetes 2 (5.26%) 3 (5.56%)
therapy 2 — diet 2 — diet,  
1 — diet  
+ insulin
Multiple pregnancies 1 (2.63%) 3 (5.56%)
number of infants 2 (twins) 7 (2 twins,  
1 triplets)
Mode of delivery
vaginal 36 (94.73%) 49 (90.74%)
caesarean 2 (5.26%) 5 (9.25%)
Pre-term delivery 1 (2.6%) 4 (7.4%)
Week of pregnancy at childbirtha 37.68 ± 6.07 
(36-41)
39.0 ± 1.48  
(27-41)
Number of neonates 39 58
a — mean ± SD (range)
Figure 2. Percentage of hypothyroid pregnant women treated with 
thyroxine or thyroxine + iodine with urinary iodine excretion 
over 150 µg/L
Rycina 2. Odsetek kobiet z jodurią powyżej 150µg/l w grupie 
ciężarnych z niedoczynnością tarczycy leczonych samą L-tyroksyną 
oraz w grupie leczonych L-tyroksyną i preparatem jodu
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a population with optimal iodine supply the percentage 
of neonates with TSH values above 5 mIU/L is under 
3% and increases to 3-19.9% in mild iodine deficiency, 
to 20–39.9% in moderate deficiency, and above 40% in 
severe iodine deficiency [5]. TSH values above 20 mIU/L 
(in Poland > 15 mIU/L) require recall of the infant for 
further examination to exclude congenital hypothy-
roidism [21–23]. In our group newborn TSH values 
(0.01–9.48 mIU/L) were within the normal range, and 
none of the children required re-examination. Surpris-
ingly, hypothyroid women treated with L-thyroxine 
and iodine supplementation had children with 33% 
higher TSH values than those who did not receive io-
dine supplements, although the difference was not sig-
nificant. Moreover, all of the neonates with TSH levels 
> 5 mIU/L were from mothers of the “thyroxine + iodine” 
group treated for overt hypothyroidism, without the 
residual functional thyroid tissue. It should be noted 
that none of the subjects took additional supplements 
containing iodine, and deliveries were conducted in 
departments that did not use iodine-containing disin-
fectants. Although, according to data from literature, 
the use of these substances results in an increase of TSH 
values above 5 mIU/L in 17.6% of neonates [24, 25], in 
our study their influence cannot be taken into account. 
Our findings could be explained by the inhibitory effect 
of iodine on foetal thyroid [26]. This kind of influence 
is especially marked in the iodine-deficient population, 
and is less pronounced when iodine supply is optimal 
[27]. Our data are inconsistent with some other studies 
indicating that increased frequency of elevated TSH 
values can serve as a marker of iodine deficiency [28]. 
We took into consideration the need to ensure the op-
timal iodine supply for pregnant women, as well as the 
consequences of iodine deficiency, especially for brain 
development of the foetus. However, in the group of 
hypothyroid women treated with L-thyroxine we did 
not show a positive influence of iodine supplementa-
tion on the foetal thyroid function parameter, which is 
the neonate TSH concentration. Similar results were 
obtained by other authors, who measured TSH con-
centrations in umbilical cord blood samples of children 
of healthy women receiving iodine supplementation 
in a dose of 150 μg daily [29]. Velasco et al. also found 
an increase of neonatal TSH in a group of pregnant 
women receiving 50–200 μg of iodine daily, but based 
on psychomotor tests performed at 3–18 months of age 
he also showed that iodine supplementation positively 
influenced on the neurological development of children 
[30]. However, recently these authors did not observe 
the positive impact of iodine supplementation during 
pregnancy on infant neurocognitive development [31], 
whereas Rebagliato et al. showed decreased psychomo-
tor and mental index scores of infants in the first year of 
life, whose mothers consumed ≥ 150 μg/day of iodine 
from supplements [32].
The vast majority of our subjects were women with 
autoimmune thyroid diseases. A limitation of our study 
was that we did not assess anti-TSH receptor binding 
antibodies, which could potentially cross the placenta 
and influence the foetal thyroids. Four of five children 
with TSH > 5 mIU/L were from women with Hashi-
moto’s disease, and we cannot exclude a potential effect 
of anti-TSH blocking antibodies on the foetal thyroids. 
We also took into account the possible inhibitory effect 
of iodine on the foetal thyroid, however, there was no 
correlation between neonatal TSH concentrations and 
maternal median urinary iodine excretion. Moreover, 
the median ioduria in mothers of children with elevated 
TSH concentrations did not differ from the rest of the 
“thyroxine + iodine” group.
One of the most common causes of elevated neo-
natal TSH concentration is prematurity. In our group, 
5 of 96 babies were premature (one from the ‘thyrox-
ine” and four from the “thyroxine + iodine” group). 
Only one of them had TSH concentration > 5 mIU/L 
(5.66 mIU/L), while the TSH concentrations of the rest 
were within the range 0.51–3.86 mIU/L.
It should be expected that an extremely high dose 
of iodine may cause foetal hypothyroidism. The ability 
of foetal thyroid to escape the Wolff-Chaikoff mecha-
nism as well as to avoid hypothyreosis is not entirely 
possible before 36 weeks of gestation [33]. The WHO 
recommendations estimate a daily dose of iodine above 
500 μg to be excessive for pregnant women [4], while 
the US Institute of Medicine defines an upper limit in 
pregnancy on the level of 1100 μg per day [34]. Inclusion 
time of iodine supplementation as well as its beneficial 
effect on neurodevelopment of children is currently 
being discussed. Velasco et al. showed a positive effect 
of iodine supplementation starting at the 10th weeks 
of gestation [30], whereas Berbel et al. observed that 
iodine lost its favourable influence when implemented 
after the 10th week of pregnancy [35]. The group of 
Berbel treated with 200 μg iodine daily 92 women since 
4–6 weeks of gestation, 102 women since 10–12 weeks 
of gestation, and 151 women after delivery. Based on 
the neurocognitive tests carried out at 18 months of age, 
those authors revealed a positive influence of this treat-
ment on children’s development only in a group sup-
plemented since 4–6 weeks of gestation, and they did 
not find differences between the group supplemented 
since the 10th week of gestation and those not receiving 
supplementation during foetal life [35]. Liesenkortter 
et al. implemented 300 μg of iodine in 38 women since 
10–12 weeks of pregnancy. Those authors compared 
the results with those of 70 non-treated women, and 
they did not show any difference in the neonatal TSH 
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concentrations [36]. It seems that the optimal dose of 
iodine, the strategy of its implementation in pregnant 
women at moderate iodine deficient areas, as well as 
the determination of the highest safe dose are still open 
questions. We realise that a limitation of our work is 
the small number of patients and the participation in 
the study of women both with overt and subclinical 
hypothyroidism. Women with partially preserved func-
tional thyroid tissue frequently need lower increment of 
L-thyroxine dose during pregnancy than patients without 
functioning gland, which suggests that their residual 
thyroid cells may to a certain extent utilise iodine for 
thyroid hormone synthesis. However, the preliminary 
results encourage us to continue research work. It seems 
reasonable to extend the study and to separate the 
groups with overt and subclinical hypothyroidism, as 
well as to assess foetal/neonatal thyroid by ultrasound. 
We conclude that our results do not provide evidence 
of a positive influence of iodine supplementation on 
thyroid function of hypothyroid pregnant women suf-
ficiently treated with L-thyroxine or their neonates. The 
results indicate the existence of iodine insufficiency in 
the population of Polish pregnant women, which might 
explain the particular sensitivity of foetal thyroid to the 
inhibitory effect of iodine. 
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